Clinical Trials Browser

Interventional × exemestane × 90 days × Clear all

NCT06179303 2026-04-16

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Phase 2 Recruiting

Anatomic Stage III Breast Cancer AJCC v8

NCT07062965 2026-04-16

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Phase 3 Recruiting

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT04852887 2026-04-15

DEBRA

Phase 3 Recruiting

Breast Neoplasms

NCT01127295 2026-04-14

PHACS

Phase 4 Completed

Breast Neoplasms

NCT01553903 2026-04-14

OXYTAM

Phase 4 Completed

Breast Neoplasms

NCT01612871 2026-04-14

MIRHO

Phase 4 Completed

Breast Neoplasms

NCT05827081 2026-04-14

Adjuvant WIDER

Phase 3 Recruiting

Breast Neoplasms, Breast Neoplasms, Male

NCT06380751 2026-04-14

EvoPAR-BR01

Phase 3 Recruiting

Advanced Breast Cancer

NCT00310180 2026-04-13

TAILORx

Phase 3 Active not recruiting

10,273 enrolled 14 charts

Breast Neoplasms

NCT01272037 2026-04-13

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Phase 3 Active not recruiting

5,018 enrolled 14 charts

Carcinoma, Intraductal, Noninfiltrating

NCT05774951 2026-04-13

CAMBRIA-1

Phase 3 Recruiting

Breast Neoplasms

NCT06169124 2026-04-13

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

Phase 2 Active not recruiting

Granulosa cell tumor of the ovary

NCT06979596 2026-04-13

OMAHA-015

Phase 2 Recruiting

Neoplasms

NCT07391774 2026-04-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Phase 3 Not yet recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT05467891 2026-04-08

RaPhLRR

Phase 2 Recruiting

Locoregional Recurrence

NCT04569747 2026-04-02

ADEPT

Phase 2 Active not recruiting

Breast Neoplasms

NCT05514054 2026-04-02

EMBER-4

Phase 3 Active not recruiting

Breast Neoplasms

NCT07499999 2026-03-30

BabyTEARS

Phase 2 Not yet recruiting

Breast Neoplasms, Carcinoma, Ductal

NCT05307705 2026-03-27

PIKASSO-01

Phase 1 Active not recruiting

Breast Neoplasms

NCT06492616 2026-03-27

ELEGANT

Phase 3 Recruiting

Breast Neoplasms, Breast Neoplasms, Male

NCT06428396 2026-03-24

LITESPARK-029

Phase 2 Recruiting

Breast Neoplasms

NCT05573126 2026-03-20

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT07174336 2026-03-20

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT00893061 2026-03-17

MNEMOSYNE

Phase 3 Completed

Breast Neoplasms

NCT06075953 2026-03-16

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Phase 2 Recruiting

Carcinoma, Intraductal, Noninfiltrating

NCT06016738 2026-03-13

OPERA-01

Phase 3 Recruiting

Breast Neoplasms

NCT06218303 2026-03-12

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Phase 1 Recruiting

Carcinoma, Intraductal, Noninfiltrating

NCT04572295 2026-03-11

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

Phase 1 Active not recruiting

Acrocephalosyndactylia, Breast Neoplasms

NCT06671912 2026-03-04

LoTam

Phase 3 Suspended

Breast Carcinoma In Situ

NCT05768139 2026-03-02

PIKALO-1

Phase 1/2 Recruiting

BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT02767661 2026-02-27

MECCA

Phase 3 Completed

Breast Neoplasms

NCT03179904 2026-02-24

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Phase 2 Active not recruiting

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT04059484 2026-02-24

AMEERA-3

Phase 2 Terminated

367 enrolled 30 charts

Breast Cancer Metastatic

NCT06507618 2026-02-24

POWER II

Phase 3 Recruiting

Breast Neoplasms

NCT03624244 2026-02-17

BFR-ESS

Phase 2 Recruiting

Endometrial Stromal Tumors

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Phase 2 Active not recruiting

Breast Neoplasms, Recurrence

NCT02947685 2026-02-12

PATINA

Phase 3 Active not recruiting

518 enrolled 15 charts

Breast Neoplasms

NCT01674140 2026-02-10

e3

Phase 3 Active not recruiting

1,939 enrolled 15 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT07395336 2026-02-09

COMBINE-01

Phase 2 Not yet recruiting

Breast Neoplasms

NCT00066690 2026-02-06

SOFT

Phase 3 Completed

3,066 enrolled 15 charts

Breast Neoplasms

NCT00066703 2026-02-06

TEXT

Phase 3 Completed

2,672 enrolled 14 charts

Breast Neoplasms

NCT05306340 2026-01-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Phase 3 Active not recruiting

Breast Neoplasms

NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

Phase 1 Recruiting

EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Phase 1 Active not recruiting

Breast Neoplasms

NCT07024173 2026-01-26

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT07019363 2026-01-21

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

Phase 3 Recruiting

Breast Neoplasms